IMCD expands FIS partner with addition of new territories

Effective immediately, IMCD Group today announced distribution partnership with Fabbrica Italiana Sintetici (FIS) for their range of active pharmaceutical ingredients (APIs), in particular: anxiolytics, anticonvulsants, antidepressants, analgesics, anti- inflammatory agents, antibacterials, antifungals, cardiovascular drugs, diuretics, oncological products and hormones. This new deal covers the following territories: Hungary, Slovenia, Serbia, Croatia, Macedonia, Bosnia and Herzegovina, Albania, Australia and New Zealand. The successful partnership of the two companies already covers a large number of countries in Maghreb, Central and Eastern Europe, most CIS countries and Russia and Austria.

 

“We are delighted about this new partnership at IMCD Business Group Pharmaceuticals, as this is the first time IMCD has an agency for an API manufacturer in Australia and New Zealand. APIs are a great complement to our comprehensive excipient portfolio which makes our offer to the pharmaceutical market complete,” stated Anne-Claire Bizet, IMCD European API Development Manager, in a press release.

 

Milan-based, FIS has custom synthesis as their core business, thus having the exclusive production of intermediates, advanced intermediates and APIs for leading pharmaceutical companies. FIS provides a wide array of integrated services to the customer, including process research and development, optimisation, and scale-up facilities to support both validation and commercial launch.

 

IMCD Pharmaceutical Business Group is the number one distributor of pharmaceutical ingredients in Europe, supplying a comprehensive range of excipients, active ingredients, speciality solvents, process chemicals and intermediates. IMCD Group is a market-leader in the sales, marketing and distribution of speciality chemicals and food ingredients.